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ORIGINAL ARTICLE
Higher Dosage of the Epidermal Growth Factor Receptor
Mutant Allele in Lung Adenocarcinoma Correlates with
Younger Age, Stage IV at Presentation, and Poorer Survival
Gerard J. Oakley III, MD, and Simion I. Chiosea, MD
Introduction: The clinical significance of epidermal growth factor
receptor (EGFR) mutant allele specific imbalance (MASI) in lung
adenocarcinomas is unknown.
Methods: EGFR MASI was characterized by sequencing electro-
pherograms (SEs) and EGFR fluorescence in situ hybridization (FISH)
in 96 prospectively tested lung adenocarcinoma patients with a median
follow-up of 20 months (all cases were EGFR mutation-positive).
Results: In 25 cases, the mutant allele (MA) peak was higher than the
wild-type allele (WA) peak, indicating the presence of EGFR MASI
(25/96, 26%). The adenocarcinomas with EGFR MASI had a 4.4-fold
higher average EGFR/Chromosome Enumeration Probe 7 ratio than
carcinomas without MASI (7.9  3.8 versus 1.8  0.6, p  0.01). A
high degree of correlation between the MA/WA ratio (SE) and the
EGFR/CEP7 ratio (FISH) (  0.757, p  0.003) validated the
quantitative nature of SE. Amplification was the most common mecha-
nism of EGFR MASI (13/21, 62%). EGFR MASI was more commonly
associated with exon 19 mutations than with exon 21 mutations (19/53,
36%, versus 6/43, 14%, p 0.015, odds ratio [OR] 3.4) and in patients
younger than 65 years (17/46, 37%, versus 8/50, 16%, p 0.019, OR
3.1). Patients with EGFR MASI presented with stage IV disease more
frequently (p 0.01, OR 3.5) and had a poorer disease-specific survival
rate (p  0.021, 54% versus 83% at 31 months).
Conclusions: EGFR MASI in lung adenocarcinomas can be as-
sessed based on SE and can be used to identify younger patients with
more aggressive disease.
Key Words: Adenocarcinoma, EGFR, Sequencing, Allelic imbalance.
(J Thorac Oncol. 2011;6: 1407–1412)
The development of lung adenocarcinoma is a multistepprocess characterized by the accumulation of genomic
alterations.1 Approximately 10% of lung adenocarcinomas in
Western populations harbor epidermal growth factor receptor
(EGFR) mutations, and 20% are characterized by EGFR gene
copy number gain (CNG).2–4 The combination of EGFR
mutations and EGFR CNG has rarely been studied.1,5,6
Similar to other oncogenes, EGFR mutations are
heterozygous in up to 80% of lung adenocarcinomas.7 Even
when the combined effect of EGFR mutations and EGFR CNG
has been studied, the individual contributions from mutant
alleles (MAs) and wild-type alleles (WAs) have largely been
ignored. TheMA/WA ratio is maintained after transcription, and
the dosage of EGFR MA may be a critical biological predictor
of tumor behavior.7 The dosage of MA can be equal to or greater
than that of the WA. The situation when MA is in excess of WA
was defined as mutant allele specific imbalance (MASI).7–9
Mechanistically, the partial dominance of MA may be due to
CNG of the MA. CNG may result from the preferential ampli-
fication of MA.7 When amplification involves a relatively large
DNA segment, it is likely to be detected by fluorescence in situ
hybridization (FISH), a method most commonly used to study
EGFR CNG in clinical samples. Polysomy of the chromosome
carrying MAmay also lead to partial dominance of the MA over
WA (i.e., partial MASI) and is also routinely identified by EGFR
FISH. In some cases, the excess of MA may be seen in
neoplastic cells with diploid karyotype and in the absence of
amplification. These cases are characterized by the virtual ab-
sence of the WA, were defined as complete MASI, and develop
through acquired uniparental disomy (UPD).7 UPD was first
described during meiosis10 and results from the inheritance of
both copies of a chromosome from the same parent (isodisomy).
Since its description, acquired UPD (arising in mitosis through
trisomy rescue or monosomy duplication) was recently shown in
colorectal and ovarian carcinomas.11,12 Importantly, UPD affects
short DNA segments and cannot be detected by FISH.
The advantage of term “MASI” is in its all-inclusive
nature—it reflects all major currently known genetic mecha-
nisms leading to the excess of MA (i.e., amplification, poly-
somy, and UPD).7,8
In many laboratories, EGFR mutation analysis is per-
formed using direct sequencing, which allows the visualiza-
tion of both MA and WA when EGFR mutations are present.
To the best of our knowledge, the EGFR MA/WA ratio has
never been characterized in clinical samples of lung adeno-
carcinoma and correlated with the outcome of lung adeno-
carcinoma patients. We hypothesized that the semiquantita-
tive assessment of sequencing electropherograms (SEs)
performed on clinical tumor samples is representative of the
actual EGFR MA/WA ratio in the tumor and identifies a
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distinct subset of patients with lung adenocarcinoma. This
hypothesis was tested by characterizing EGFR MASI in 96
prospectively accrued lung adenocarcinomas that harbored
EGFR mutations. Furthermore, we correlated EGFR MASI
with patient age, EGFR/Chromosome Enumeration Probe 7
(CEP7) FISH data, clinical stage, and disease-specific sur-
vival (DSS).
PATIENTS AND METHODS
Clinicopathological Characteristics of Studied
Patients
Ninety-six consecutively diagnosed lung adenocarcino-
mas positive for EGFR exon 19 (n  53) or exon 21 (n  43)
mutations were included in this study. These cases were identi-
fied at the University of Pittsburgh Medical Center (UPMC)
from 2005 to 2010 through routine EGFR testing of all newly
diagnosed lung adenocarcinomas. Sixty-nine resected adenocar-
cinomas (51 lobectomies, 7 wedge resections, 7 segmentecto-
mies, 3 pneumonectomies, and 1 bilobectomy), 66 of which
were stage I through III, and 27 biopsied adenocarcinomas, 21 of
which were stage IV, were studied. All cases were restaged
according to the seventh edition of the American Joint Commit-
tee on Cancer manual. Eighty-nine patients were White, 4 were
African American, 2 were Asian, and 1 was of Middle Eastern
descent. Only 10 patients received neoadjuvant chemotherapy
before EGFR testing, and none of the patients had prior treat-
ment with tyrosine kinase inhibitors. The median follow-up was
20 months. Smoking history was available for 95 of 96 patients.
There were 45 never smokers and 50 ever smokers (former or
current). The high prevalence of smokers in this cohort is
consistent with previously reported smoking rates among pa-
tients treated at UPMC (41 never smokers and 296 smokers).3
The clinicopathological features of the studied patients are sum-
marized in Table 1.
This article is the result of a quality improvement project
and was approved by the UPMC Total Quality Council.
EGFR Exon 19 and Exon 21 Mutation Analysis
EGFR exon 19 and 21 mutation analysis was performed
as previously described.3 Briefly, for resected tumors, targets
containing more than 75% tumor cells were manually microdis-
sected from 4-m unstained histological sections obtained from
formalin-fixed paraffin-embedded tissue. DNA was isolated
from each formalin-fixed paraffin-embedded target using the
DNeasy tissue kit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. To detect mutations, the DNA was
amplified with primers flanking exon 19 (forward primer 5-
CCCAGCAATATCAGCCTTAGGTG-3 and reverse primer
5-CCACTAGAGCTAGAAAGGGAAAGAC-3) or exon 21
(forward primer 5-CCTCACAGCAGGGTCTTCTC-3 and re-
verse primer 5-CCTGGTGTCAGGAAAATGCT-3) of the
EGFR gene in separate reaction tubes for each primer set. PCR
products (40 cycles) were sequenced in both the sense and
antisense directions using the BigDye Terminator v3.1 cycle
sequencing kit on an ABI 3130 automated sequencer (Applied
Biosystems, Inc., Foster City, CA) according to the manufactur-
er’s instructions. The sequences were analyzed using Mutation
Surveyor software (SoftGenetics, LLC, State College, PA) and
compared with reference sequence NM__005228.3 along the
full length of each exon.
EGFR FISH Analysis
EGFR FISH analysis was successfully performed on 81
cases as previously described using a standard method with a
dual-color EGFR SpectrumOrange/CEP7 SpectrumGreen probe
(Vysis, Inc., Downers Grove, IL).3 EGFR FISH was not per-
formed on 14 biopsies due to insufficient material, and in one
resection specimen EGFR FISH failed despite three hybridiza-
tion attempts. Sections were deparaffinized, dehydrated in eth-
anol, air-dried, and then digested with protease K (0.5 mg/ml) at
37°C for 28 minutes. The slides were denatured at 75°C for 5
minutes and dehydrated in ethanol; the probes were also dena-
tured for 5 minutes at 75°C before hybridization. Slides were
hybridized overnight at 37°C and washed in 2x SSC/0.3% NP40
at 72°C for 2 minutes, and the nuclei were counterstained with
DAPI/Antifade 1 (Vysis, Inc., Downers Grove, IL). Each FISH
assay included normal lung tissue sections as a negative control.
Analyses were performed using a fluorescence microscope
(Nikon Optiphot-2 and Quips Genetic Workstation, Melville,
NY). The histological areas previously selected on the hematox-
ylin and eosin-stained sections were identified on the FISH
slides. Only individual and well-delineated cells were scored,
and overlapping cells were excluded from the analysis. At least
60 cells were scored for each case, and the EGFR/CEP 7 ratio
was recorded for each case. Amplification was defined as an
EGFR/CEP 7 ratio of2. High polysomy was defined as40%
of cells with 4 EGFR copies (highly correlated with CEP7
hyperdiploidy, i.e., 2 CEP7 signals per nucleus, data not
shown).13,14
TABLE 1. Clinical and Laboratory Characteristics of Patients
with Lung Adenocarcinoma Positive for EGFR Mutation,










Male:female 25:71 17:36 8:35
Mean age (yr) 65 64 67
Smoking historya (n)
Never smokers 45 21 24
Ever smokers 50 31 19
Clinical stage (n)
I–III 72 39 33
IV 24 14 10
MA:WAb
MA  WA (n) 25 19 6
MA  WA (n) 71 34 37
EGFR/CEP7 FISH ratioc (average) 3.4 4 2.6
aSmoking history was not available for one patient.
bThe mutant/wild-type allelic ratio was determined based on assessment of the
sequencing electropherogram. The association between exon 19 mutation and MA 
WA is statistically significant (2 test, p  0.015, odds ratio  3.4, 95% CI, 1.2–9.6).
cEGFR FISH was successfully performed in 45 cases with EGFR exon 19 mutations
and in 36 cases with EGFR exon 21 mutations. The EGFR/CEP7 FISH ratio was not
statistically different between exon 19 and 21 (Student’s t test, p  0.05).
EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization;
MA, mutant allele; WA, wild-type allele.
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Determination of the Ratio between the MA
and WA by Semiquantitative Assessment of
the MA and WA Peak Heights on SEs
Peak heights of the MA and WA were compared and
grouped into two categories: MA higher than WA (MA 
WA) and MA lower than WA (MA  WA) (Figure 1). Any
increase of the MA over WA was defined as MASI. For cases
with EGFR exon 19 deletions, the MA/WA ratio was deter-
mined by comparing the first five different peaks starting
from the deletion point. To test whether the MA WA ratio
as determined using SEs is an accurate semiquantitative
representation of allelic imbalance in the tumor, peak heights
of MA and WA waves were measured using a ruler from the
midpoint of the peak to the SE baseline. For deletion muta-
tions, the average of the first five different peaks was calcu-
lated using the modification of Soh et al. (MA height/WA
allele height). Cases with MAWA were selected to test the
correlation between the MA/WA ratio and EGFR/CEP7 ratio
as determined using FISH. The validation set included cases
with MAWA and EGFR/CEP7 FISH ratio2. Cases with
MA  WA and an EGFR/CEP7 FISH ratio 2 were ex-
cluded from the correlation analysis because the likely mech-
anism of EGFR MASI in these cases is chromosome 7
polysomy, UPD, or homozygous mutation; UPD and ho-
mozygous mutations involve short segments of DNA and are
not detected by FISH.
Statistical Analysis
DSS was measured from the date of surgery to the date of
death. Living patients were censored at the date of the last
available clinical information. Survival probabilities were calcu-
lated using the Kaplan-Meier method and compared among
different groups and subgroups (log-rank test). Statistical anal-
ysis was performed using SPSS 19 (Somers, New York, NY).
RESULTS
Identifying EGFR MASI: Comparing SEs and
FISH
In 25 cases, the MA peak was higher than the WA peak,
indicating the presence of EGFR MASI (25/96, 26%). Twe-
nty-one case (21/25) had sufficient material for EGFR FISH.
On average, the EGFR/CEP7 ratio was 4.4-fold higher in
EGFR MASI cases (7.9  3.8 versus 1.8  0.6, p  0.01,
Table 2). Thirteen of 21 (62%) cases with EGFR MASI
showed an EGFR/CEP7 FISH ratio of 2, indicating that
amplification of the EGFR MA is the most common mecha-
nism of EGFR MASI. We noted that 10 of 13 cases showed
an EGFR/CEP7 ratio 5. Both EGFR/CEP7 ratio cutoffs
(2 and 5) were associated with EGFR MASI (2, p 
0.001, 2 test; 5, p  0.001, Fisher’s exact test).
The MA/WA ratio, as assessed using SE, showed a
high degree of correlation with the EGFR/CEP7 ratio (Figure
2; Spearman’s correlation coefficient,   0.757, p  0.003).
In 1 of 25 cases with EGFR MASI, the dominant sequence
after the deletion point was that of the MA (Figure 3A), and
the EGFR/CEP7 ratio in this case was 39 (Figure 3B).
Six of 21 (29%) cases with EGFR MASI showed an
EGFR/CEP7 FISH ratio of 2 and EGFR high polysomy
(Figures 3C, D).
Two of 21 EGFR MASI cases did not show EGFR
amplification or high polysomy. The types of observed EGFR
MASI are summarized in Table 3.
FIGURE 1. A–C, Representative cases of EGFR exon 21
codon 858 T to G point mutations. The variation in peak
heights for mutant and wild-type alleles on sequencing elec-
tropherograms (SEs) is shown. Portions of the SE surround-
ing the point mutation (arrows) were scanned. The top row
represents the nucleotide sequence of the dominant poly-
merase chain reaction product, as recognized by the se-
quencing software (“GGCKGGC,” where “K” stands for a
nucleotide unrecognized by the software due to the colo-
cation of two nucleotides). Each of the four nucleotides
was labeled with a unique fluorescent dye (e.g., T  thy-
midine, A  adenosine). A, Representative case with the
mutant allele peak lower than the WA peak (MA  WA).
B, Representative case with the mutant allele peak approx-
imately threefold higher than the wild-type allele peak
(MA  WA). C, Representative case with the mutant allele
peak approximately ninefold higher than the wild-type
allele peak (MA  WA).
TABLE 2. EGFR Mutant Allele Specific Imbalance and
Clinicopathological Features of Patients with Lung






Mean agea (yr) 59 67
Age groupsb (yr)
65 (n  46) 17 29
65 (n  50) 8 42
Clinical stagec
I–III (n  72) 14 58
IV (n  24) 11 13
EGFR/CEP7 FISH ratiod (average) 7.9 1.8
aStatistically significant, two-tailed independent groups Student’s t test for means,
p  0.001.
bThe association between age (65 yr) and MA  WA is statistically significant
(2 method, p  0.019, odds ratio OR  3.1, 95% CI, 1.2–8; with hypothesis-driven
directionality).
cThe association between stage IV and MA  WA is statistically significant (2
method, p  0.01, OR  3.5, 95% CI, 1.3–9.5; with hypothesis-based directionality).
dStatistically significant, Student’s t test with unequal variance (two-tailed, p 
0.01).
EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization;
MA, mutant allele; WA, wild-type allele.
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Clinicopathological Correlates of EGFR MASI
Patients with EGFR MASI carcinomas were 8 years
younger and more likely to present with stage IV disease (p
0.01, odds ratio  3.5, 95% confidence interval [CI] 1.3–9.5)
(Table 2). EGFR MASI was seen more frequently in carci-
nomas that harbored EGFR exon 19 mutations (19/25, 76%).
The patient’s gender, smoking history, exon harboring
mutation (19 versus 21), and EGFR/CEP7 ratio were not
significantly associated with DSS. As expected, stage IV
patients had worse DSS than stage I–III patients (Figure 4A).
Importantly, patients with carcinomas characterized by
EGFR MASI showed worse DSS (Figure 4B). As EGFR
MASI was associated with younger age and stage IV disease
at the time of diagnosis, a subgroup analysis was performed
to determine whether EGFR MASI held an independent
prognostic value. In a subset of patients with stage I–III
adenocarcinoma, patients with EGFR MASI showed a trend
of more aggressive disease (Figure 4C). Finally, even among
patients younger than 65 years, carcinomas characterized by
EGFR MASI showed poorer DSS (Figure 4D).
DISCUSSION
Lung adenocarcinomas are characterized by complex ge-
netic alterations. For instance, EGFR may be activated by
mutations or CNG, either alone or in combination. A variety of
methods are used to characterize EGFR status, including chro-
FIGURE 2. Correlation between the EGFR mutant and wild-
type allelic ratio as determined by sequencing electrophero-
gram (SE) and the EGFR/CEP7 ratio as determined by fluores-
cence in situ hybridization (Spearman’s bivariate correlation
test). The correlation coefficient () is 0.757 and indicates a
high degree of correlation (p  0.003).
FIGURE 3. Correlation of EGFR fluorescence in situ hybridization (FISH) with the semiquantitative evaluation of sequencing
electropherograms (SEs). Portions of SE surrounding the deletion points (red arrows) were scanned. The top row was typed in
and represents the wild-type sequence, and the second row represents the actual sequence of the dominant polymerase chain
reaction product. A, SE of a case with an EGFR exon 19 deletion and without an easily identifiable wild-type allele after the
deletion point. These laboratory values belonged to a deceased 44-year-old white nonsmoking woman who presented with
stage IIIb (pT2b N2) lung adenocarcinoma and developed recurrence associated with distant metastases 8 months after the
initial surgery. B, EGFR FISH corresponding to the SE in 3A (EGFR/CEP7 ratio  39). C, Mutant allele peaks are higher than
the wild-type allele peaks. However, mutant allele specific imbalance is not accompanied by amplification (see panel D). D,
The EGFR/CEP7 ratio is 1.1. The presence of four EGFR and CEP7 signals per nucleus indicates tetraploidy. Polysomy and am-
plification represent two mechanisms of mutant allele specific imbalance that are detectable by FISH. Red signal, Texas red/
rhodamine—EGFR probe; green signal, fluorescein isothiocyanate—CEP7 probe; blue signal, 4,6-diamidino-2-phenylindole—
outlining the nuclei.
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mogenic in situ hybridization,15 Southern blot analysis,16
qPCR,17,18 and, most commonly, EGFR FISH.14 In routine
clinical application, however, none of these techniques can
characterize the individual contributions of MA and WA to
EGFR protein levels.
Soh et al.7 demonstrated that direct sequencing is a
valid method of quantifying the MA/WA ratio. The quanti-
tative nature of SE was demonstrated using several tech-
niques, including subcloning, plasmid mixture experiments,
and restriction fragment length polymorphism combined with
band intensity measurement on gel electrophoresis.7 The
correlation between the MA/WA ratio and EGFR FISH (i.e.,
amplification) presented here further demonstrates that SE
can detect EGFR MASI in clinical samples.
Previous studies on EGFR MASI in lung adenocarcino-
mas made an extensive effort to account for the DNA derived
from non-neoplastic cells (Table 4). “Contamination” by non-
neoplastic cells is of concern when determining the MA/WA
ratio in clinical samples. For instance, the median proportion of
tumor DNA extracted from nonmicrodissected clinical samples
of non-small cell lung carcinoma was 57% and from control cell
lines 89 to 95%.7 The review of hematoxylin and eosin slides
and manual microdissection limits the proportion of the nontu-
mor DNA. The smaller remaining amount of non-neoplastic
tissue would randomly affect all clinical samples. Nontumor
DNA increases the WA peak, decreases the MA/WA ratio, and
decreases the ability of SE to detect MASI.
Considering this limitation, we show for the first time
that EGFR MASI as identified by SE correlates with distinct
clinical features. The presence of EGFR MASI identified a
subset of patients who were younger, more likely to present
with stage IV disease, and had shorter DSS, overall and in a
subset of patients younger than 65 years (Figure 4).
It is difficult to compare the incidence of EGFR MASI in
this study with that in other studies because (1) previous studies
did not routinely specify which EGFR exon (19 or 21) showed
MASI and (2) the numbers of patients of Asian descent in those
studies easily exceeded that in our study (Table 4).7,8,19
The combined interpretation of EGFR FISH and SE
indicates that the most common mechanism of MASI is CNG
by amplification (as previously described by Soh et al.)
(Table 3). Yokoyama et al.16 anecdotally commented that
“sequence analysis demonstrated that the mutation signals of
FIGURE 4. Disease-specific survival (DSS) anal-
ysis based on the Kaplan-Meier method. A, DSS
by stage: stages I–III (events [i.e., death from
disease]  6/55, 24%; estimated mean sur-
vival  53 months, 95% CI 47–60) versus stage
IV (events  4/17, 24%; estimated mean sur-
vival  36 months, 95% CI 24–47). B, DSS and
the dosage of the EGFR mutant allele. MA  WA
(mutant allele peak height lower than that of
the wild-type allele; events  4/52, 8%; esti-
mated mean survival  55 months, 95% CI 48–
62) versus MA  WA (mutant allele peak height
higher than that of the wild-type allele, EGFR
mutant allele specific imbalance; events  6/20,
33%, estimated mean survival  37 months,
95% CI 29–45). C, To control for stage, the
DSS analysis was performed in a subgroup of
patients with stage I to III. MA  WA: events 
3/43, 7%; estimated mean survival  56
months, 95% CI 50–63 versus MA  WA:
events  3/12, 25%, estimated mean survival 
34 months, 95% CI 28–39. D, To control for
patient age, the DSS was analyzed in a sub-
group of patients younger than 65 years. MA 
WA: events  2/21, 10%; estimated mean sur-
vival  57 months, 95% CI 50–65 versus MA 
WA: events  5/15, 33%, estimated mean sur-
vival  32 months, 95% CI 25–38.
TABLE 3. Types of EGFR Mutant Allele Specific Imbalance:
Combined Interpretation of EGFR FISH and Sequencing






Unknown, presumed UPD, or homozygous mutation 2/21 (10)
aPercentages do not add up to 100% due to rounding.
EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization.
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[amplified lung carcinomas] were dominant, with 5 being
completely lost for wild-type signal,” concluding that the MA
was selectively amplified.
Two EGFR MASI cases showed an EGFR/CEP7 ratio of
2 and no chromosome 7 polysomy. Assuming that the WA
signal is derived entirely from the admixed normal tissue, it is
possible that MASI is the result UPD in these cases. If so, then
the incidence of UPD in our report (2/21, or about 10%) is
comparable to that reported previously by Soh et al. (22%).7
The number of cases analyzed in this study was limited
by the low prevalence of EGFR mutations in lung adenocar-
cinomas affecting Western population. Our conclusions re-
quire further validation in larger cohorts including patients of
Asian descent and treated with tyrosine kinase inhibitors.
In summary, EGFR MASI as determined using SE is a
valid way to further subclassify EGFR exon 19- and 21-mutated
lung adenocarcinomas.EGFRMASI in lung adenocarcinomas also
identified younger patients with more aggressive disease.
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Studied Material:
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Mutated Adenocarcinomas
(n) Method
EGFR MASI Incidence of Acquired
Uniparental
Disomy ReferenceExon 19 Exon 21
10 NSCLC cell linesa Subcloning 7/7 2/3 Minority of cases 8
76 PCRb 32/76 (42.1%), not specified
by exonc
Not studied 19





19/53 (36%) 6/43 (14%) Cannot be determined with
certainty
Current study
aEGFR copy number was determined using qPCR. In this study, the “mutant allele was almost always in excess compared with the wild-type allele.”
bAmplification of the wild-type allele could not be determined with certainty.
cSixty percent of tumors were from East Asians. EGFR exon 19 mutations were almost twice as common as EGFR exon 21 mutations.
dFifteen of 45 patients were of Asian descent.
EGFR, epidermal growth factor receptor; MASI, mutant allele specific imbalance; NSCLC, non-small cell lung cancer; PCR, polymerase chain reaction; SNP, single nucleotide
polymorphism; SE, sequencing electropherogram.
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